



## ***Morgan Clarke***

**ASSOCIATE**

**Boston**

**P +1 617 648 9328**

**Morgan is a corporate and securities associate in our Boston office.**

Morgan specializes in the representation of emerging growth companies throughout their lifecycles.

Morgan's practice focuses on general corporate counseling, venture capital financings and mergers and acquisitions. Morgan represents a wide variety of technology companies from consumer internet, software, telecommunications and entertainment technology industries, as well as a number of leading venture capital firms.

Prior to attending law school, Morgan did business and product development with various pharmaceutical and technology startups in the Bay Area. While attending law school, Morgan served as a legal intern for the University of Notre Dame Community Development Clinic, where she advised local businesses and nonprofits on issues such as entity formation, tax exempt status and other small business matters.

## Credentials

### EDUCATION

- Notre Dame Law School, J.D.  
*cum laude*
- University of San Francisco, B.A. & B.S., Business Administration  
*summa cum laude*

### BAR ADMISSIONS

- Massachusetts

## Focus Areas

Corporate Governance & Strategy

Mergers & Acquisitions

Fund Investments in Companies

Seed, Venture and Growth Financings

Public Companies/Public Offerings

## Related News & Insights

### CLIENT NEWS

Evident Vascular Announces Series B Financing

### CLIENT NEWS

QuEra Computing Announces \$230M Financing

### CLIENT NEWS

Be Biopharma Announces \$82M Financing to Advance Gene Therapy

### FIRM NEWS

Gunderson Dettmer Commemorates 2024 Women's History Month and International Women's Day

### CLIENT NEWS

Evident Vascular Announces \$35M Series A Led By Vensana Capital

CLIENT NEWS

Spark Capital Led \$125M Series C Financing of Headway

CLIENT NEWS

TCV leads Instawork \$60M Series D

CLIENT NEWS

Avoro Ventures Participates in Hemab Therapeutics \$135M Series B Financing

CLIENT NEWS

Testing Platform AtomicJar Announces \$25M Series A Financing

CLIENT NEWS

Photys Therapeutics Announces \$75M Series A Financing to Advance its New Class of Bifunctional Molecules

CLIENT NEWS

Spark Capital Leads \$115M Series B Financing of Afresh to Help Food Waste

CLIENT NEWS

Carbon Biosciences Emerges From Stealth Mode With a \$38M Series A Financing

CLIENT NEWS

Whyline Acquisition by CLEAR